Diligence memo · auto-generated · as of July 2, 2026
Neuro42, Inc.
Neuro42, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Neuro42, Inc. operates in Other Health Care, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neuro42, Inc. has raised $22M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2024-09-04.
Most recent recorded round closed around 2024-09-04.
Valuation (modeled)modeled
Provath models Neuro42, Inc. at approximately $96M (range $37M–$167M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.63× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 22 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 2.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Other Health Care peers (5377 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.